Apremilast (Otezla) Phase 2B Clinical Trial Presentation

Presented By
Wasaf Hasan Lione
Introduction
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor. It works by inhibiting the enzyme PDE4. Apremilast is
indicated for the management of moderate to severe plaque psoriasis and psoriatic arthritis in adult patients.
Introduction
• Apremilast is a phosphodiesterase 4 (PDE4) inhibitor. It works by inhibiting the enzyme PDE4, which leads to
increased intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels modulate
inflammatory and immune responses, resulting in anti-inflammatory effects and the suppression of cytokine
production involved in the pathogenesis of psoriasis and psoriatic arthritis. This mechanism helps reduce
inflammation and control symptoms associated with these conditions.